This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.

Start Date03 Mar 2025

Sponsor / Collaborator

VA Office of Research and Development

[+1]

NCT06378957 / Not yet recruitingPhase 1IIT

Behavioral Pharmacology of Orally Administered THC and D-limonene

The current clinical trial will investigate the effects of orally administered d-limonene (limonene), delta-9-tetrahydrocannabinol (THC) and the combination in healthy adult volunteers.

Start Date01 Mar 2025

Sponsor / Collaborator

The Johns Hopkins University

NCT03734731 / Not yet recruitingNot Applicable

Clinical Trial Policy Study for the Objective Comparison of Cannabis Vs Opioids (CVO) Pain Management and Therapy Types for Circulatory and Chronic Pain Issues

Our purpose for the study is to find safer, less intrusive, better preforming non-addictive products, as an alternative therapy for pain relief and to help alleviate the opioid epidemic ongoing in America today.

Start Date03 Feb 2025

Sponsor / Collaborator

American Association of Sensory Electrodiagnostic Medicine

100 Clinical Results associated with Dronabinol

100 Translational Medicine associated with Dronabinol

100 Patents (Medical) associated with Dronabinol

11,541

Literatures (Medical) associated with Dronabinol

01 Feb 2025·EUROPEAN NEUROPSYCHOPHARMACOLOGY

Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review

Review

Author: Cammà, Guido ; van der Meer, Pim B ; van der Meer, Pim B. ; Verdouw, Monika P. ; Groenink, Lucianne ; Verdouw, Monika P ; Batalla, Albert

Interest in cannabinoids' therapeutic potential in mental health is growing, supported by evidence of the involvement of the endocannabinoid system in psychiatric disorders such as anxiety, depression, and addiction. While the major cannabinoids cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) have been more extensively researched, approximately 120 minor cannabinoids from the cannabis plant have been identified. Although some displayed promising pharmacological profiles, research on their application for psychiatric disorders is fragmented. This systematic review evaluates, for the first time, both preclinical and clinical studies exploring minor cannabinoids' therapeutic potential in psychiatric disorders. 22 preclinical studies and one clinical study were included, investigating various minor cannabinoids in substance use disorders, anxiety disorders, depressive disorders, trauma and stressor-related disorders, psychotic disorders, neurodevelopmental disorders, and eating disorders. Despite the heterogeneous results and the moderate to high risk of bias in several articles, certain compounds demonstrate promise for further investigation. Δ8-tetrahydrocannabidivarin (Δ8-THCV) exhibited potential for nicotine addiction; Δ9-tetrahydrocannabidivarin (Δ9-THCV) for psychotic-like symptoms; cannabidiolic acid methyl ester (CBDA-ME) alleviated anxiety and depression-like symptoms, and cannabidivarin (CBDV) autism spectrum disorder-like symptoms.

01 Feb 2025·BEHAVIOURAL BRAIN RESEARCH

Effects of repeated voluntary oral consumption of synthetic delta-9-tetrahydrocannabinol on locomotor activity and cannabinoid receptor 1 expression

Article

Author: Cain, Mary E. ; Miki, C. Azuma ; Laux, Dylan A. ; Laux, Dylan A ; Cain, Mary E ; Azuma, Miki C

As cannabis legalization expands, preclinical studies continue to investigate the impact of repeated exposure to delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound in the plant. With the increasing popularity of cannabis infused foods, the rise of THC in medicinal applications have also expanded. The present study addresses a critical gap in existing literature by investigating the behavioral and neurobiological effects of low-dose edible THC in a preclinical rodent model. Adult male rats were administered synthetic-THC (Dronabinol) (0.0625 mg/kg, 0.125 mg/kg, and 0.25 mg/kg) or vehicle (sesame oil) through edible cookies, 90 min prior to eight locomotor sessions. Locomotor activity significantly increased in both 0.0625 mg/kg and 0.25 mg/kg THC groups, indicating a dose-dependent relationship. Repeated 0.25 mg/kg THC administration dose-dependently reduced cannabinoid receptor 1 expression in the hippocampus. The observed neurobiological change from low dose oral THC advances our understanding of repeated cannabis use. These findings also emphasize the importance of refining rodent models for translational relevance.

01 Jan 2025·ADDICTIVE BEHAVIORS

Derived psychoactive cannabis product perceptions and use among a sample of US young adults

Article

Author: Cavazos-Rehg, Patricia A ; Rossheim, Matthew E. ; LoParco, Cassidy R ; LoParco, Cassidy R. ; Yang, Y Tony ; Yang, Y. Tony ; Berg, Carla J. ; Rossheim, Matthew E ; Cui, Yuxian ; McCready, Darcey M. ; Berg, Carla J ; Romm, Katelyn F ; Wang, Yan ; Romm, Katelyn F. ; McCready, Darcey M ; Cavazos-Rehg, Patricia A.

AIMS:

To characterize derived psychoactive cannabis product (DPCP) perceptions and use among US young adults.

METHODS:

We analyzed 2023 survey data among 4,031 young adults (ages 18-34), comprising ∼ 50 % reporting past-month cannabis use. Multivariable regressions examined sociodemographics, cannabis use, and DPCP risk perceptions in relation to: 1) past-month DPCP use (yes/no), 2) past-month number of DPCP use days, and 3) among those reporting no past-month DPCP use, future likelihood of DPCP use.

RESULTS:

In this sample (M_age = 26.3, 59.8 % female, 64.9 % White, 19.4 % Hispanic), DPCP awareness (67.5 %), lifetime use (41.7 %), and past-month use (24.4 %) differed by past-month cannabis use versus nonuse (87.0 % vs 48.8 %, 68.7 % vs 15.9 %, 45.6 % vs 4.2 %, respectively). Those aware learned about them mainly from friends/family (44.5 %) and believed DPCPs were required to be tested and approved to be safe (70.3 %) or were approved by the US Food and Drug Administration (59.0 %). Those who ever used DPCPs most often used delta-8 (69.7 %) and delta-9 (44.4 %) THC and for curiosity (55.5 %), belief of federal legality (34.1 %), and friends' suggestion (34.0 %). Correlates of past-month DPCP use, using more frequently, and higher likelihood of future use were: lower DPCP perceived harm and higher perceived addictiveness. Living where non-medical cannabis was illegal, higher perceived social acceptability, being Black (vs. White), and past-month cannabis use were also correlated with past-month use (but not frequency) and future likelihood of use.

CONCLUSIONS:

Efforts are needed to better understand DPCPs' risks and correct consumer misperceptions. Relatedly, DPCP regulation, including marketing and distribution, is crucial.

427

News (Medical) associated with Dronabinol

04 Dec 2024

·www.accesswire.com

Ovation Science Licensee Launches Innovative Transdermal Cannabis Products in Pennsylvania

VANCOUVER, BC / ACCESSWIRE / December 4, 2024 / (CSE:OVAT)(OTC PINK:OVATF) - Ovation Science Inc. ("Ovation" or the "Company"), with its patented topical and transdermal cannabis products powered by its proprietary skin delivery technology Invisicare®, announces the official launch of its products in Pennsylvania through its licensee: PA Options for Wellness Inc. ("PA Options").The launch marks Ovation's second licensee in the USA and is part of the Company's on-going strategy to seek leading cannabis companies as licensees, state-by-state across the US. Pennsylvania's medical cannabis market boasts over 850,000 registered patients and caregivers, with more than 170 dispensaries throughout the state. PA Options, founded in 2014, operates six dispensaries under the Vytal Options brand and has over 32,000 registered medical patients. The Ovation Science products will be launched through-out Pennsylvania under the brand name "Mood".PA Options operates a 65,000-square-foot, state-of-the-art cannabis grow/processing and production facility. The company collaborates with Penn State University College of Medicine on Medical Cannabis Research and with Penn State University Harrisburg on research exploring the medicinal properties of hemp and flax.Terry Howlett, CEO of Ovation Science, stated, "We are excited about collaborating with PA Options as both companies are focused on offering the best, most effective products to patients. Our expansion with PA Options will establish our products in a market that really needs our science-based solutions. Their impressive production facility and extensive distribution network will ensure our products resonate with dispensaries and patients across the state. By collaborating with PA Options, we're bringing this innovative approach directly to patients who need advanced, research-backed medical cannabis solutions."Tom Trite, CEO of PA Options, stated: "Our mission has always been about more than just selling medical cannabis - it's about improving patient outcomes and quality of life. Ovation's scientifically developed products align perfectly with our commitment to transforming patient care. Their Invisicare® technology represents a quantum leap in transdermal cannabinoid delivery, offering our patients a potentially more effective, targeted approach to managing their health conditions. We're not just adding a new product line; we're introducing a medical cannabis treatment that could significantly improve how patients experience relief."Unlike traditional cannabis products, Ovation's innovative formulations leverage advanced pharmaceutical-grade drug delivery technology that dramatically enhances cannabinoid absorption. and enables substantially more CBD, THC, and other cannabinoids to be delivered through the skin. Studies show the company's products have a 10 times greater release of CBD through the skin compared to other tested products. The products can be used for both topical skin issues and transdermal absorption into the bloodstream.Ovation continues to expand its U.S. growth strategy with notable developments in multiple states. The Company reports ongoing success in Nevada through its licensee Planet 13 with its Medizin product line, demonstrating a strong market presence in the state. Further expanding its footprint, the Company is preparing to enter the Missouri market. This expansion, through its licensee MidWest Roots, is anticipated to occur in January 2025. Additionally, the Company announces the termination of its previously disclosed licensing agreement with Stash House Distribution for Oklahoma, New Mexico, and Mississippi, allowing for new potential licensees to enter these states.About PA Options for Wellness, Inc.PA Options for Wellness was founded with research in mind and a focus on patient outcomes and quality of life. Its mission is to combine plant science and medicine to bring top-quality, innovative products to the medical market and transform the lives of their patients while adhering to strict ethical standards. The company operates a 65,000 square foot, state-of-the-art cannabis grow/processing and production facility and six patient-centric cannabis dispensaries throughout Pennsylvania. The company also collaborates with medical leaders and universities in the state to advance patient care and research.About Ovation Science Inc.Ovation Science Inc. and its wholly-owned subsidiary; Ovation Science USA Inc., is a research and development company that develops topical and transdermal CBD/THC and other cannabinoid products which are out-licensed and also distributed under Ovation's own brands; ARLO CBD Beauty and InVibe® MD ("wellness" line); all powered by its patented Invisicare® skin delivery technology. Invisicare enhances the delivery of ingredients to and through the skin and is protected by patents and proprietary formulations which cannot be duplicated. With over 20 years of pharmaceutical drug delivery experience, Ovation's management and science teams have created a unique pipeline of over thirty proprietary medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from royalties on licensees' sales and the sale of Invisicare, along with revenue from its own product sales. Ovation has offices in Vancouver, Canada and Las Vegas, USA.Stock symbols: CSE:OVAT and OVATF in the USA on OTC Markets.Websites: CORPORATE: www.ovationscience.comWELLNESS: www.invibemd.com BEAUTY: www.arlocbdbeauty.comForward-Looking StatementsInformation set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance of sales and acceptance of its products in any of the states cited, continued sales in dispensaries or in retail markets or expansion to other states. There are no guarantees of future performance or changes to regulations. Ovation Science Inc. cautions that all forward-looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.'s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease.Neither the Canadian Securities Exchange, OTC Markets nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.CORPORATE INQUIRIES:Doreen McMorran: [email protected] PH: 604-982-5700SOURCE: Ovation Science Inc.

License out/in

26 Nov 2024

·www.drugs.com

American College of Rheumatology, Nov. 14-19

The annual meeting of the American College of Rheumatology was held this year from Nov. 14 to 19 in Washington, D.C., and attendees included rheumatology specialists, physicians, scientists, and other health professionals. The conference featured presentations focusing on the latest advances in the diagnosis and treatment of arthritis as well as other rheumatic and musculoskeletal diseases. During one presentation, Chuan-Ju Liu, Ph.D., of the Yale University School of Medicine in New Haven, Connecticut, discussed how the sodium channel Nav1.7 represents a novel and actionable target to preserve joint structure and slow osteoarthritis progression, addressing not only pain but also structural deterioration. Liu highlighted recent discoveries linking sodium channel Nav1.7 to the regulation of joint structure in osteoarthritis. He outlined how sodium channels in chondrocytes play a critical role in maintaining cartilage integrity and how targeting these channels could mitigate cartilage degeneration. "Preclinical studies demonstrated that modulating Nav1.7 can prevent joint deterioration, suggesting a promising therapeutic approach," Liu said. "Although still in the early stages, this research points toward the potential for developing sodium channel inhibitors or modulators as disease-modifying treatments for osteoarthritis. Over time, this approach may complement or reduce reliance on existing treatments like nonsteroidal anti-inflammatory drugs, which primarily address symptoms and often have side effects." Press Release In another presentation, Daniel Clauw, M.D., of the University of Michigan in Ann Arbor, discussed cannabis therapy for chronic pain among patients with rheumatic diseases. Currently, there are very few randomized clinical trials evaluating the effectiveness and safety of cannabis products. In addition, the results of these studies can vary based on dose, mode of administration, and an individual's metabolism. It is also difficult to determine how much cannabidiol (CBD) and tetrahydrocannabinol (THC) are contained within cannabis products. However, Clauw stressed that cannabis can still be a relatively safe and effective option for the treatment of chronic pain. "Cannabis products likely have a role in treating pain but more research needs to be done regarding what cannabis products work for what types of pain," Clauw said. "We know that CBD is quite safe and legal in all of the United States and people should try that before venturing to THC, which may be helpful in some but has far more potential side effects." Press Release Lihi Eder, M.D., of the Women's College Hospital and University of Toronto, discussed how understanding sex-related differences in psoriatic arthritis is critical to developing approaches that consider the sex of the patient in disease management. Male and female patients with psoriatic arthritis may present differently, with female patients having more pain and disability and a lower response to biologic therapies compared with their male counterparts. Eder said that the mechanisms behind these findings remain unclear, but the differences could be related to biological mechanisms such as pain processing, immune function, and the pharmacokinetics of drugs. They could also be due to sociocultural factors, including coping mechanisms, support systems, and access to care. "Considering sex/gender in patient care could improve outcomes. For example, use of more sensitive imaging such as ultrasound to investigate the source of pain may be more important in females and could provide insights about the cause of pain and inform therapy," Eder said. "More research is needed to identify mechanisms for the observed differences." Press Release ACR: Inebilizumab Reduces Risk for Flares in IgG4-Related Disease TUESDAY, Nov. 19, 2024 -- For patients with immunoglobulin G4-related disease, inebilizumab reduces the risk for flares and increases the likelihood of flare-free complete remission, according to a study published online Nov. 14 in the New England Journal of Medicine to coincide with the annual meeting of the American College of Rheumatology, held from Nov. 14 to 19 in Washington, D.C. Read Full Text ACR: Colchicine No Benefit for Painful Knee Osteoarthritis TUESDAY, Nov. 19, 2024 -- Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis, according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 14 to 19 in Washington, D.C. Read Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

20 Nov 2024

·www.globenewswire.com

MAPS Successfully Clears Path for Cannabis Research through FDA Formal Dispute

After three years of negotiation with the FDA, MAPS has successfully secured FDA clearance to conduct a clinical trial, MJP2, to examine the use of smoked cannabis for the treatment of PTSD symptoms among ~320 Veterans in Michigan and two other statesMJP2’s purpose is to generate safety data about cannabis use that mirrors real-world consumption, developing an evidence base to inform medical professionals MAPS’ successful negotiations with the FDA will benefit future clinical researchers investigating cannabis as a potential medical treatment for serious health conditions SAN JOSE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) Division of Psychiatry Products has cleared the Multidisciplinary Association for Psychedelic Studies (MAPS)’ Phase 2 study of smoked cannabis in Veterans for the treatment of PTSD (MJP2) to proceed. Initially placed on partial clinical hold by the FDA in 2021, MJP2 is a randomized, placebo-controlled study of 320 Veterans suffering from moderate to severe PTSD who have previously used cannabis. Funded by the Michigan Veteran Marijuana Research Grant Program, the study is designed to investigate the inhalation of high THC dried cannabis flower, versus placebo cannabis, with the daily dose being self-titrated by participants. Over three years, the FDA issued, and MAPS responded to, five partial clinical hold letters which halted the progression of MJP2. On August 23, 2024, MAPS responded to the FDA’s fifth clinical hold letter by submitting a Formal Dispute Resolution Request (FDRR) to resolve the continued scientific and regulatory disagreement with the Division on four key issues: 1) the proposed THC dose of the cannabis flower product, 2) smoking as a delivery method, 3) vaping as a delivery method, and 4) the enrollment of cannabis naïve participants. “Despite the increasingly widespread use and acceptance of cannabis in patients with PTSD, labeled as ‘medical use’ in many states, there is still a lack of high-quality, controlled data on the safety and effectiveness of cannabis use that reflects real-world consumption patterns. MAPS designed MJP2 to bridge this evidence gap by studying the ‘real-world’ use of inhaled cannabis to understand its potential benefits and risks in treating PTSD. These data are critical to inform patients, medical providers, and adult-use consumers when considering cannabis in treatment plans for the management of PTSD, pain, and other serious health conditions, yet regulatory obstacles have historically made it difficult or impossible to conduct meaningful research on the safety and effectiveness of cannabis products typically consumed in regulated markets. The updated opinions expressed by the FDA in response to the FDRR demonstrate a willingness to recognize the value of high-quality data on the risks and potential benefits of the already-occurring widespread use of cannabis for managing PTSD. Removing barriers to research is a key part of MAPS’ mission, and we are glad to have negotiated a resolution to these long-standing obstacles in cannabis research to support all future cannabis researchers.” Allison Coker, Ph.D., Director of Cannabis Research, MAPS MAPS achieved a successful resolution on key issues when the FDA indicated that they would allow MJP2 to proceed with self-titration dosing of smoked cannabis with a THC potency that corresponds to what is commercially available in states permitting legal medical and/or adult-use cannabis programs. The FDA also no longer objects to vaporization as a delivery method. However, the use of any specific vaporization device requires additional information on its mechanics to assess its safety for use with patients. Therefore, the FDA cleared the study to proceed with smoking administration but retained the partial clinical hold on the vaping device until the requested information is provided. Additionally, the FDA maintains that cannabis naïve participants would be subject to unreasonable risk in the study. While MAPS disagrees that cannabis naïve participants smoking or vaporizing cannabis in an amount of their choosing for a 5-week period would expose them to “unreasonable and significant risk,” MAPS updated the protocol to require that all participants must have “prior experience inhaling (smoking or vaporizing) cannabis.” “MAPS takes pride in leading the way to open new research pathways by challenging the FDA to think differently. We debated with the FDA for more than 15 years to be able to conduct rigorous research for MDMA-assisted therapy for PTSD, a novel treatment approach for FDA reviewers, then and now. Similarly, our cannabis work challenges FDA’s typical approach to scheduled dosing and administration of drugs. MAPS refused to compromise the study design in order to fit into the standard box of FDA thinking in order to ensure that cannabis research reflects cannabis use.”Rick Doblin, Ph.D., Founder and President, MAPS “Our Veterans are in dire need of treatments that can ease their challenging symptoms of PTSD. In my own practice, Veteran patients have shared how smoking cannabis helped them manage their PTSD symptoms more than traditional pharmaceuticals. Suicide among Veterans is an urgent public health crisis, but it’s solvable if we invest in researching new treatments for life-threatening health conditions like PTSD. MJP2 will generate data that doctors, like myself, can use to develop treatment plans to help people manage their PTSD symptoms.” Sue Sisley, M.D., Principal Investigator of MJP2 In the absence of high-quality data related to cannabis, much of the information available to patients and regulators is rooted in prohibition and focused only on potential risks, without consideration of potential benefits. Within the United States, millions of Americans are smoking or vaporizing cannabis to manage or treat their symptoms. The updated opinions expressed by the FDA demonstrate a willingness to recognize the value of high-quality data on the risks and potential benefits of the already-occurring widespread use of cannabis for managing PTSD. ABOUT MAPSFounded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS previously sponsored the most advanced psychedelic-assisted therapy research in the world and continues to support psychedelic and marijuana research with a focus on the people and places most impacted by trauma. MAPS incubated Lykos Therapeutics, a drug-development public benefit company, and The Zendo Project, a leader in psychedelic harm reduction. Since MAPS was founded, philanthropic donors and grantors have given more than $140 million to advance psychedelic research, change drug policy, and shape culture.

Phase 2

100 Deals associated with Dronabinol

External Link

KEGG	Wiki	ATC	Drug Bank
D00306	Dronabinol	A04AD10	DB00470

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anorexia	US	Alkem Laboratories Ltd.	31 May 1985
Nausea	US	Alkem Laboratories Ltd.	31 May 1985
Vomiting	US	Alkem Laboratories Ltd.	31 May 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chemotherapy-induced nausea and vomiting	NDA/BLA	CA	Tetra Bio-Pharma, Inc.	01 May 2023
Sleep Apnea, Obstructive	Phase 3	US	RespireRx Pharmaceuticals, Inc.	01 Feb 2023
Decrease in appetite	Phase 3	-	Solvay SA	15 Feb 2007
Alzheimer Disease	Phase 2	US	Unimed Pharmaceutical, Inc.	29 Jul 1996
Depressive Disorder	Phase 2	US	Unimed Pharmaceutical, Inc.	29 Jul 1996
Parkinson Disease	Preclinical	CA	Pike Therapeutics, Inc.Startup	01 Nov 2024
Cachexia	Discovery	-	Avicanna, Inc.	14 Feb 2022
Multiple Sclerosis	Discovery	US	Unimed Pharmaceutical, Inc.	14 Aug 2003
Pain	Discovery	US	Unimed Pharmaceutical, Inc.	13 Oct 1999

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NTIASD1 (Company_Website) Manual	Phase 1/2	Autism Spectrum Disorder	14	NTI164	raxkuekjoj(ihtggikpyl) = qpnylkriqa gologoshfd (jipeogfsdj )	Positive	01 Dec 2024
NCT03804840 (AIS, CTgov)	Early Phase 1	Thrombocytopenia 1	72	Placebo (Placebo)	nyvlfaymtb(vsypcfvlcn) = gxgcgtdizi qxvqdgyiqw (uyshjogddh, nimmkctomd - ojtsvrezvh) View more	-	19 Sep 2024
				Dronabinol (7.5 mg THC)	nyvlfaymtb(vsypcfvlcn) = wrkvbixhsl qxvqdgyiqw (uyshjogddh, ryyiwjcmsp - chftyqaqfx) View more
NCT03809546 (IDT, CTgov)	Early Phase 1	Thrombocytopenia 1	60	dextrose (Placebo)	hjhilpkoqd(xlafuwbzug) = dlywhcdhhi zuuiscnmyn (fppaqvfsbn, ntzpiatrxq - gqqawxnkrk) View more	-	03 Jul 2024
				Dronabinol (7.5 mg THC)	hjhilpkoqd(xlafuwbzug) = adwvwzbxrb zuuiscnmyn (fppaqvfsbn, rxbwchaxtc - apppxdwpwf) View more
NCT03099005 (CTgov)	Phase 2	HIV Infections \| Neuralgia	5	Cannabis (Low CBD Session)	rennzipsad(jptkouylba) = mjutoisqmc uegjootkda (vmrtgqjmof, jefdmghoib - aptnhvbeed) View more	-	18 Jun 2024
				Cannabis (Medium CBD Session)	rennzipsad(jptkouylba) = zeouegczst uegjootkda (vmrtgqjmof, mshoeqlkgi - phwkxutrmh) View more
ACTRN12619000037101 (ASCO2024)	Phase 2	Advanced cancer	144	10mg/ml THC:10mg/ml CBD combination oil	jsthejhcoo(klcmkoftic) = 26/69 and 12/72 ixyltuucgu (ttlleipuno ) View more	Negative	24 May 2024
				Placebo
NCT05192239 (CTgov)	Early Phase 1	-	17	Placebo (Placebo)	vhnofxpjlz(mxjapwpwjh) = qcobjefsyh yeasleawwp (oaoawqchay, gwrbigcxiu - bjdzsysnso) View more	-	22 Apr 2024
				THC 5 (10 mg THC)	vhnofxpjlz(mxjapwpwjh) = vcqsbnbuud yeasleawwp (oaoawqchay, cooclzvxae - ovbrytkcla) View more
NCT04294966 (ART, CTgov)	Early Phase 1	Thrombocytopenia 1	24	Dextrose (Placebo)	sgserpkjis(fohulpwikm) = oyeyibpidw tweifbbhoh (chmzxlawrb, zoxqxlqjil - yqcdiexcwo) View more	-	09 Nov 2023
				Dronabinol (7.5 mg THC)	sgserpkjis(fohulpwikm) = kqfpudoxem tweifbbhoh (chmzxlawrb, asjrpijtfa - jnlrtzziuc) View more
NCT03609853 (CTgov)	Phase 1	-	53	Placebo (Placebo)	rpzezerziq(fjyjumoazd) = mfgznjebck plaufdyzod (adargyyudh, puarzpqnmv - rldjvatnrq) View more	-	18 Oct 2023
				limonene+THC (Vaporized Low THC)	rpzezerziq(fjyjumoazd) = lmgqfugpcv plaufdyzod (adargyyudh, etcoaddyzo - ivvjdaidfm) View more
NCT02460692 (CTgov)	Phase 2	Low Back Pain \| Neuralgia	131	Placebos (Placebos)	egdsanviea(bwsuujqgra) = vtjvmdufta lrlgcdbcad (hxajmalejf, qhyjuwhkdx - bjpvtycnul) View more	-	28 Sep 2023
				Dronabinol (Dronabinol)	egdsanviea(bwsuujqgra) = ancyyllrkw lrlgcdbcad (hxajmalejf, ilbrfrhuwz - ieheucytve) View more
IEC2023	Not Applicable	Drug Resistant Epilepsy Add-on	19	cannabidiol-enriched oils (Responder to CBD)	ejbyupzjgl(fdcwidvggg) = qgmybtktex peqalqinjp (bwjigvbptt )	Positive	04 Sep 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis